American next-generation sequencing companies in the USA have developed and improved significantly in recent years. They provide the basic needs for genetic material research and disease diagnosis. Sequencing helps doctors make accurate diagnoses for patients with various diseases. Leading companies are implementing technologies to personalize treatment and improve therapy outcomes.
Next-generation sequencing companies in the US include players such as InheriNext and Fabric Genomics. Congenica, GeneDx, and 3billion are also actively working in the market with their own developments. All of them compete for customers and are constantly improving their products.
InheriNext is a platform from Compass Bioinformatics for the diagnosis of hereditary diseases. It uses WGS and WES technologies to analyze patients' genetic material. The platform is based on artificial intelligence with transparent algorithms for prioritizing options. Data processing takes 3 to 15 minutes. This speed makes InheriNext one of the best Next generation sequencing services.
InheriNext has been approved by the FDA as Class I Software as a Medical Device. The system complies with international quality standards and is ISO certified. These certificates confirm the safety of the product for use in medical institutions. Doctors use InheriNext to diagnose various diseases, including Fabry disease. The platform detects important variants in the GLA gene and helps doctors make the right decisions.
Fabric Genomics offers Next generation sequencing services for analyzing WGS and WES data. The system's algorithms find pathological variants quickly and efficiently within a working day. The technology identifies 98% of causative mutations in the top 5 results of each analysis. This allows doctors to review results in 15 minutes without delay.
Laboratories using Fabric GEM process 10 times more samples without increasing staff. The system automatically reduces the number of variants to less than five for specialist review. This saves time and resources for medical institutions when analyzing massive parallel sequencing data. The implementation took place in leading US institutions, including Rady Children's Institute. The platform is also used by Broad Clinical Labs and Intermountain Primary Children's Laboratories to diagnose rare diseases.
Congenica has developed a single platform for next generation sequencing companies analysis of patient genome data in an automated manner. The system processes both hereditary mutations and somatic changes in the genome. The analysis process begins with NGS and ends with the creation of an interactive report. The platform is CE-IVD labeled for rare and oncological diseases.
The system uses artificial intelligence to identify priority genetic variants in patients. The developers claim to speed up diagnosis by 85% of the usual time. The analysis of genetic data is four times faster compared to traditional methods. The reliability of the process has been confirmed by studies at ASHG with the automation of classification according to ACMG standards.
Congenica's oncology module operates in a fully automatic mode without human intervention. Data processing time is reduced from several hours to a matter of minutes. The system takes into account therapeutic recommendations from regulatory authorities in different countries. The platform supports FDA, EMA, and MHRA standards when generating clinical opinions.
GeneDx has been operating in the clinical genetics market since 2000. The company was founded by scientists from the US National Institutes of Health. They have developed more than 139 different genetic tests for clinical use. These tests diagnose more than 620 different diseases by analyzing gene panels.
The company has created its own database of genetic variants for accurate diagnosis. Their specialists quickly process test results and prepare detailed reports. Doctors receive support in interpreting complex genetic data from the GeneDx team. The introduction of genetic tests into clinical practice helps patients with hereditary diseases. The quality of medical care is improving thanks to accurate diagnoses from GeneDx.
3billion, one of the prominent next generation sequencing companies in USA, combines NGS analysis with the GEBRA platform for genomic data processing. The system converts raw data into conclusions for clinical use. The analysis process is automatic with minimal human intervention. The company focuses on diagnosing rare diseases for maximum accuracy.
The system allows unlimited reinterpretation of data until the diagnosis is made. The analysis results are updated based on new discoveries in genetics. The knowledge base is constantly expanding due to the addition of new scientific data. This ensures that the conclusions are relevant even years after the initial testing.
3billion uses artificial intelligence to compare data with patient phenotypes. The database contains information on 75,000 patients from more than 70 countries. The system automatically finds similar cases to compare genetic variants. This approach significantly reduces the time to diagnosis for patients with rare diseases.
